Evaluation of the Medicines and Diagnostics Manufacturing Transformation Fund and the Life Sciences Innovative Manufacturing Fund - GOV.UK Cookies on GOV.UK We use some essential cookies to make this website work. We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services. We also use cookies set by other sites to help us deliver content from their services. You have accepted additional cookies. You can change your cookie settings at any time. You have rejected additional cookies. You can change your cookie settings at any time. View cookies Research and analysis Evaluation of the Medicines and Diagnostics Manufacturing Transformation Fund and the Life Sciences Innovative Manufacturing Fund Findings from the early‑stage evaluation of the Medicines and Diagnostics Manufacturing Transformation Fund and its successor, the Life Sciences Innovative Manufacturing Fund. From: Department for Science, Innovation and Technology and Office for Life Sciences Published 14 April 2026 Documents Evaluation of the Medicines and Diagnostics Manufacturing Transformation Fund and the Life Sciences Innovative Manufacturing Fund Ref: DSIT 2026/006 HTML Details The funds provided capital grants to support life sciences manufacturing projects in the UK, with objectives including strengthening domestic manufacturing capability, supporting economic growth and enhancing health resilience. The evaluation was commissioned by the Office for Life Sciences and delivered by Ipsos, covering Medicines and Diagnostics Manufacturing Transformation Fund ( MDMTF ) and Life Sciences Innovative Manufacturing Fund ( LSIMF ) projects funded through the 2021 and 2022 calls for proposals. It includes: a process evaluation, to assess efficiency and effectiveness of delivery processes an early impact evaluation, to assess whether the funds have begun to deliver on objectives a value for money evaluation The findings are intended to inform the ongoing design and delivery of LSIMF2025-30 and to support future decisions on life sciences manufacturing policy. Updates to this page Published 14 April 2026 Sign up for emails or print this page Is this page useful? Maybe Thank you for your feedback Help us improve GOV.UK To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab